Atlantic Coastal Acquisition Ii (ACAB) Return on Assets ROA from the second quarter of 2026 to second quarter of 2025 and for the year 2026, Average High and Low, Fundamental Ratios from Jun 30 2026 to Jun 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Atlantic Coastal Acquisition Corp Ii  (NASDAQ: ACAB)


Atlantic Coastal Acquisition Ii's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics


What is Atlantic Coastal Acquisition Ii's ROA in the second quarter of 2026?
Atlantic Coastal Acquisition Corp Ii achieved a return on average assets (ROA) of 54.09 % in its second quarter of 2026 a new company high.

ROA has improved compared to -1.01% in the first quarter of 2026, due to net income growth.

However, within the Healthcare sector 18 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 2664, from total ROA ranking in the first quarter of 2026 at 5033.

What is ROA?


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Assets (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter
Y / Y Total Assets Change 50.47 % 145.44 % -83.26 % -77.47 % -52.14 %
Y / Y Net Income Change - - - - -
Net Income (TTM) in million 2 0 -3 -12 -12
Return On Assets (TTM) 54.09 % -1.01 % -127.88 % -331.05 % -243.65 %
ACAB's Total Ranking # 2664 # 5033 # 4710 # 4730 # 4750
Total Assets (TTM) in million 5 7 1 2 3
Seq. Total Assets Change -23.66 % 545.81 % -37.58 % -51.11 % 24.53 %
Seq. Net Income Change - - - - -

ACAB's 5 Years Annual ROA >> Back to ACAB Management Effectiveness >> Compare ACAB ROA to its Competitors


Return On Assets Company Ranking
Within: No.
Industry # 5
Sector # 19
Overall # 65

Return On Assets Statistics
High Average Low
54.09 %
-71.62 %
-375.29 %
(Jun 30 2026)   (Sep 30 2025)





Financial Statements
Atlantic Coastal Acquisition Ii's Assets $ 5 million ACAB's Balance sheet
Atlantic Coastal Acquisition Ii's Income $ -1 million Quarterly ACAB's Income Statement
ACAB's Income by Division See ACAB's Income by Division



Annual Return On Assets (Dec 31 2025)
FY 2025		 (Dec 31 2024)
FY 2024		 (Dec 31 2023)
FY 2023		 (Dec 31 2022)
FY 2022
FY
Y / Y Total Assets Change -83.26 % -83 % -87.97 % - -
Total Assets in million 1 6 37 311 0
Y / Y Net Income Change - - 218.12 % - -
Net Income in million -3 -7 3 1 0
Annual Return On Assets -272.06 % -113.87 % 7.55 % 0.29 % -

ACAB's 5 Years Annual ROA >> Back to ACAB Management Effectiveness >> Compare ACAB ROA to its Competitors



More Return On Assets Ratios
ACAB's' Return on Assets at Yahoo Finance
Biotechnology & Pharmaceuticals Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
ACAB's Roa Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for ACAB's Competitors
Subscribers only: Roa for Atlantic Coastal Acquisition Ii's Suppliers
Subscribers only: Return On Assets for ACAB's Customers

You may also want to know
ACAB's Roi ACAB's Inventory Turnover Ratio ACAB's Growth Rates ACAB's Dividend Comparisons
ACAB's Profitability Ratios ACAB's Asset Turnover Ratio ACAB's Dividend Growth
ACAB's Roe ACAB's Valuation Ratios ACAB's Financial Strength Ratios ACAB's Dividend Payout Ratio



Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector ROA
Capforce Inc   141.40 %
Protagenic Therapeutics Inc new  137.58 %
Elutia Inc   108.72 %
Silexion Therapeutics Corp  99.09 %
Arbutus Biopharma Corp  96.04 %
Pulmatrix Inc   94.81 %
Quince Therapeutics Inc   88.46 %
Interpace Biosciences Inc   85.91 %
Oncotelic Therapeutics Inc   81.75 %
Rigel Pharmaceuticals Inc  72.27 %
Actinium Pharmaceuticals Inc  71.73 %
Sanuwave Health Inc   71.60 %
Exelixis Inc   70.51 %
Rallybio Corporation  64.51 %
Oramed Pharmaceuticals Inc  64.18 %
Fortress Biotech Inc   60.88 %
Atlantic Coastal Acquisition Corp Ii  54.09 %
Lensar Inc   47.48 %
Elite Pharmaceuticals Inc   46.11 %
Omeros Corporation  46.05 %
Q32 Bio Inc   45.18 %
Aurinia Pharmaceuticals Inc   44.95 %
Agenus Inc  44.86 %
Earth Science Tech Inc   44.02 %
Liquidia Corporation  36.30 %
Ironwood Pharmaceuticals inc   34.34 %
Idexx Laboratories Inc  33.61 %
Tg Therapeutics Inc   33.59 %
Meiragtx Holdings Plc  29.37 %
Indivior Pharmaceuticals Inc   28.21 %

Date modified: 2026-09-12T06:26:36+00:00


Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.